A corrigendum on
Chronic Pyruvate Supplementation Increases Exploratory Activity and Brain Energy Reserves in Young and Middle-Aged Mice
by Koivisto, H., Leinonen, H., Puurula, M., Hafez, H. S., Alquicer Barrera, G., Stridh, M. H., et al. (2016). Front. Aging Neurosci. 8:41. doi: 10.3389/fnagi.2016.00041
In the Original Research article there was an error in the Section “Treatment” under the section “Methods” about the estimated daily intake of pyruvate:
“With the average food intake of 4 g this corresponds to 800 mg of pyruvate/day, which is at the upper range of effective pyruvate doses in earlier in vivo studies (Suh et al., 2005; Fukushima et al., 2009; Isopi et al., 2014).”
As correctly stated in the Abstract, the estimated dose was 800 mg of pyruvate/kg/day.
The corrected version of this section is shown below:
Treatment
Chronic Pyruvate Administration
The test group (PYR) received experimental chow supplemented with 0.6 % (w) of Na-pyruvate (Safe Diets, Augy, France). The control group (STD) received the same basic rodent chow (A04, Safe Diets). With the average food intake of 4 g this corresponds to 800 mg of pyruvate/kg/day, which is at the upper range of effective pyruvate doses in earlier in vivo studies (Suh et al., 2005; Fukushima et al., 2009; Isopi et al., 2014). Acute pyruvate administration. The mice received Na-pyruvate (Sigma, St. Louis, MO, USA) 500 mg/kg i.p. or the same molar concentration of NaCl (260 mg/kg i.p.). This single dose affords neuroprotection against cortical concussion injury and increases brain glucose and pyruvate levels as measured by in vivo microdialysis (Fukushima et al., 2009). All cage labels about the treatment groups were coded so that the researchers running behavioral tests or assays on post-mortem samples were blinded as to the treatment.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Hennariikka Koivisto1, Henri Leinonen1, Mari Puurula1, Hani S. Hafez2, Glenda Alquicer Barrera3, Malin H. Stridh4, Helle S. Waagepetersen4, Mika Tiainen5, Pasi Soininen5, Yuri Zilberter6 and Heikki Tanila1*
* 1A. I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland
* 2Biology Department, Faculty of Science, Suez University, Suez, Egypt
* 3Institute of Physiology, Czech Academy of Sciences, v.v.i., Prague, Czechia
* 4Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
* 5NMR Metabolomics Laboratory, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
* 6Institute de Neurosciences des Systèmes, Aix Marseille Université, Institut National de la Santé et de la Recherche Médicale UMR_S 1106, Marseille, France
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
© 2017. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.